REBIF (interferon beta-1a) and AVONEX (interferon beta-1a) are currently used for the treatment of Australians living with relapsing forms of MS. Recently, there were some changes announced to their listing on the PBS.
From 1 April 2023, AVONEX will no longer be available on the Pharmaceutical Benefits Scheme (PBS) for Australians living with MS.
MS Australia is delighted to announce over $3 million of funding towards MS research in 2023. The twenty-two new projects address MS Australia’s priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.
CEO Rohan Greenland discusses the dramatic escalation in the number of people in Australia living with MS and urges the government to take action so that we can work together to turn the tables on MS. Â
A recent study from researchers in Perth has explored the impact of COVID-19 on people living with MS and MS carers, investigating both the highs and lows of the pandemic. A deeper understanding of these experiences can help inform future crises as they unfold, to ensure the best care and health management possible for people living with MS, their carers and loved ones.
International researchers have developed a cutting-edge tool to identify a rare subtype of cell in the brain potentially involved in MS.
Judith Webb was a much-loved primary school teacher, volunteer, wife and mother. Her generosity and courage motivated her husband Bob to allocate a portion of his Will to MS research.
MS Australia has awarded over $3 million in grants for multiple sclerosis (MS) research, providing a major boost in the fight against this increasing and accelerating disease.
The number of Australians living with multiple sclerosis (MS) is increasing at a significant and accelerating rate.
